Introduction: Choosing the right CRO for Injectable Drug Development is one of the most important strategic decisions pharmaceutical and biotechnology […]
Selecting the Right CRO for Injectable Drug Development Read More »
Introduction: Developing a biosimilar monoclonal antibody involves far more than demonstrating analytical similarity with the reference product. One of the
Introduction Sponsors of generic drugs can improve their time-to-market and increase the likelihood of regulatory approval by utilizing comprehensive CDMO
Introduction This comprehensive research report examines the advanced scientific, aseptic manufacturing, and regulatory strategies necessary for the successful development and
Introduction The Biosimilar Interchangeability Designation in the USA represents a significant legal and regulatory framework established under the Biologics Price
Introduction: E&L testing vs drug device compatibility studies comes down to one core distinction: E&L testing asks what chemicals migrate
Introduction The critical operational and compliance difference between a nitrosamine screening method and a confirmatory method is primarily defined by
What Is the Difference Between a Nitrosamine Screening Method and a Confirmatory Method? Read More »
Introduction The primary biophysical distinction between PLGA 50:50 and PLGA 75:25 is defined by their monomer composition, specifically the ratio
Introduction: When comparing ICH M7 vs FDA Nitrosamine Guidance, both share the same objective — protecting patients from potentially carcinogenic
ICH M7 vs. FDA Nitrosamine Guidance: Regulatory Framework Alignment and Key Differences Read More »
Introduction Poly(lactic-co-glycolic acid) (PLGA)-based particulate delivery systems offer a highly biocompatible and biodegradable platform for protecting fragile biomolecules while enabling
